Disease relevance of Danitracene

• Preventive treatment of migraine with mini-doses of danitracene [1].
• WA-335 did not prevent catalepsy induced with physostigmine [2].
• WA-335 depresses reserpine-induced hypothermia, particularly in mice, but does not affect ptosis induced with this neuroleptic [3].

Psychiatry related information on Danitracene

• WA-335 acts synergistically with amphetamine in which it potentiates stereotyping and enhances motility [3].
• Determination of psychoactivity and cerebral bioavailability of danitracene (WA 335) by quantitative pharmaco-EEG and psychometric investigations [4].

High impact information on Danitracene

• Three antiserotonin compounds, p-chlorphenylalanine, mianserine and danitracen, were investigated for their influence on amphetamine stereotypy in correlation with concentration of this amine in blood serum and brain tissue [5].
• The effects of tricyclic antidepressants; imipramine and doxepin, and of new antidepressants; mianserin, danitracen, trazodone, viloxazine and zimelidine, on seizures kindled from the rabbit amygdala were examined [6].
• The period of active attempts to escape from the cylinder was lengthened by injecting the animals with the following antidepressants: imipramine (IMI), amitriptyline (AMI), doxepin (DOS), mianserin (MIA), danitracen (DAN), iprindole (IPR), as well as cyproheptadine (CYP), even if they were administered only once [7].
• The results obtained indicate that DX blocks central 5-HT receptors, like the two other antidepressants, mianserin and danitracen [8].
• WA 335 (danitracen): a preliminary evaluation of a potential antidepressant compound. A comparative double-blind study with WA 335 and amitriptyline in the treatment of depressive patients [9].

Chemical compound and disease context of Danitracene

• Influence of WA-335, a factor which blocks serotonin receptors, on neuroleptic-induced catalepsy [2].
• Joint administration of WA-335 and L-DOPA with an inhibitor of peripheral decarboxylase, or WA-335 and amantadine produced a stronger antagonistic effect (spiroperidol catalepsy) than either of these substances separately [2].

Biological context of Danitracene

• WA-335 does not affect the drop in body temperature or stereotype induced with apomorphine [3].

Anatomical context of Danitracene

• The action of compound WA-335 on the central nervous system [3].

Analytical, diagnostic and therapeutic context of Danitracene

• A positive correlation (decrease of stereotypy as well as the concentration of amphetamine in serum and brain) was found only for danitracen. p-Chlorphenylalanine and mianserine premedication decreased serum and brain tissue concentration of amphetamine, but enhanced amphetamine stereotypy effect [5].

References